Oliver Sims

At Biofidelity, we’re working toward a future where more people around the world have access to the life-changing power of genomics. Our novel molecular technologies simplify genomic analysis, so more patients have access to the information needed to ensure the best possible outcomes. Our vision doesn’t end with oncology, though. Our revolutionary technologies will pave the way for tomorrow’s yet-unknown scientific breakthroughs. We believe in the transformational power of genomics. We believe that with imagination and ingenuity, anything is possible. Most importantly, when it comes to humanity’s most complex problems, we believe in the power of simple.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

At Biofidelity, we’re working toward a future where more people around the world have access to the life-changing power of genomics. Our novel molecular technologies simplify genomic analysis, so more patients have access to the information needed to ensure the best possible outcomes. Our vision doesn’t end with oncology, though. Our revolutionary technologies will pave the way for tomorrow’s yet-unknown scientific breakthroughs. We believe in the transformational power of genomics. We believe that with imagination and ingenuity, anything is possible. Most importantly, when it comes to humanity’s most complex problems, we believe in the power of simple.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

Follow this profile to stay up-to-date with our mission: improving peoples lives by maximising the potential of science & technology.

Octopus Ventures, part of Octopus Group, is one of the largest and most active venture capital investors in the UK and Europe. We’re on a mission to invest in the people, ideas and industries that will change the world. We back entrepreneurs ─ from the first cheque their business receives, right through to IPO. We manage £1.8bn and are investing in more than 200 businesses, focusing on the companies solving three of the world’s biggest problems: those building a sustainable planet, empowering people, and revitalising healthcare. We know what it takes to build a successful business. We support founders through our strong teams, sector expertise and deep networks, using our people and talent to help them build a better tomorrow.

Meltwind Advisory, founded by Jonathan Milner, supports bringing game-changing technology to market by building a collaborative ecosystem of innovative companies that aim to transform health outcomes.